Regentis Stock Jumps 502.7% on EU Surgeon Training for GelrinC Implant
RGNT•Regentis stock surged 502.67% to $9.04 on trading volume of 178.16 million shares after the company announced European surgeon training for its GelrinC knee cartilage repair implant. GelrinC, approved in the European Union, targets a U.S. market estimated at $3 billion and positions the regenerative-medicine firm for a major commercial launch.
1. Stock Performance Surge
Regentis Biomaterials shares soared 502.67% to close at $9.04 on trading volume of 178.16 million, with an intraday high of $15.50 and low of $1.69 as investors reacted to strategic program news.
2. European Surgeon Training Program
The company will begin training European orthopedic surgeons on GelrinC, its cell-free knee cartilage repair implant approved in the European Union, marking a critical step toward regional commercial launch.
3. Market Potential and Commercial Strategy
GelrinC targets a U.S. market valued at approximately $3 billion and leverages EU launch momentum to secure distribution partnerships and prepare for subsequent regulatory filings in North America.
